The spectrum of Vogt-Koyanagi-Harada disease in South India
- PMID: 17318321
- DOI: 10.1007/s10792-007-9046-9
The spectrum of Vogt-Koyanagi-Harada disease in South India
Abstract
Purpose: To report the clinical spectrum of Vogt-Koyanagi-Harada (VKH) disease in a tertiary care center in South India.
Methods: Medical records of patients diagnosed with VKH disease who presented between January 1995 and December 2003, with a minimum follow-up of one year were reviewed.
Results: Of the 45 patients, 38 (84.44%) were female. The median age was 37 years (SD +/- 14.23) and median duration of symptoms was 30 days (range 1 day to 1 year). 75.5% (34/45) presented with bilateral anterior uveitis. Posterior segment presentation included disc edema (31/45), bilateral serous retinal detachments (26/45), vitritis (17/45) and sunset glow (8/45). Extra ocular manifestations were seen in only 4/45 (tinnitus: 2, meningismus: 1, poliosis: 1). 97.7% (44/45) received oral Prednisolone (1 mg/kg body weight) for a median duration of 14 months. 69% (31/45) received additional three pulses of intravenous methylprednisolone and 22% (10/45) received a single infusion of intravenous Cyclophosphamide. One patient received intravitreal triamcinolone injection 53.33% (24/45) were treated with additional immunosuppressants. At the first visit, best corrected visual acuity (BCVA) was > or =20/40 in 23 eyes (25.55%) and < or =20/400 in 37 eyes (41.11%). At one year, 61 eyes (67.77%) achieved BCVA of > or =20/40 while 12 eyes (13.33%) had BCVA < or =20/400. Complicated cataract, glaucoma and macular scar were the major complications encountered.
Conclusions: Majority of patients with ocular VKH presented with anterior uveitis and serous retinal detachments and disc edema. Extra-ocular signs are rare in our patients. Visual prognosis is good with treatment with adequate long-term corticosteroids and immunosuppressive agents.
Similar articles
-
Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.Acta Dermatovenerol Croat. 2023 Dec;31(4):229-231. Acta Dermatovenerol Croat. 2023. PMID: 38651852
-
Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India.Retina. 2010 Jul-Aug;30(7):1113-21. doi: 10.1097/IAE.0b013e3181c96a87. Retina. 2010. PMID: 20168275
-
Vogt-Koyanagi-Harada disease in Hispanic patients.Int Ophthalmol. 2007 Apr-Jun;27(2-3):143-8. doi: 10.1007/s10792-006-9017-6. Epub 2007 Mar 23. Int Ophthalmol. 2007. PMID: 17380271
-
Vogt-Koyanagi-Harada disease.Surv Ophthalmol. 2017 Jan-Feb;62(1):1-25. doi: 10.1016/j.survophthal.2016.05.002. Epub 2016 May 27. Surv Ophthalmol. 2017. PMID: 27241814 Review.
-
Vogt-Koyanagi-Harada syndrome in children.Ocul Immunol Inflamm. 1998 Sep;6(3):155-61. doi: 10.1076/ocii.6.3.155.4041. Ocul Immunol Inflamm. 1998. PMID: 9785605 Review.
Cited by
-
Genetic analysis of innate immunity in Behcet's disease identifies an association with IL-37 and IL-18RAP.Sci Rep. 2016 Oct 24;6:35802. doi: 10.1038/srep35802. Sci Rep. 2016. PMID: 27775096 Free PMC article.
-
VKH disease in the elderly: Variations in clinical course as compared to VKH disease in adults.Indian J Ophthalmol. 2024 Jul 1;72(Suppl 4):S580-S583. doi: 10.4103/IJO.IJO_2185_23. Epub 2024 Jan 8. Indian J Ophthalmol. 2024. PMID: 38189444 Free PMC article.
-
Gender differences in vogt-koyanagi-harada disease and sympathetic ophthalmia.J Ophthalmol. 2014;2014:157803. doi: 10.1155/2014/157803. Epub 2014 Mar 5. J Ophthalmol. 2014. PMID: 24734166 Free PMC article. Review.
-
Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease.BMC Ophthalmol. 2018 Jan 15;18(1):6. doi: 10.1186/s12886-018-0670-0. BMC Ophthalmol. 2018. PMID: 29334924 Free PMC article.
-
Genetic variations of IL-12B, IL-12Rβ1, IL-12Rβ2 in Behcet's disease and VKH syndrome.PLoS One. 2014 May 23;9(5):e98373. doi: 10.1371/journal.pone.0098373. eCollection 2014. PLoS One. 2014. PMID: 24859272 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources